Loading data for GALT — first visit, this takes a few seconds.

알림

Galectin Therapeutics Inc... (GALT)

NasdaqCM: GALT · 실시간 가격 · USD

4.02

-0.12 (-2.90%)

종가 기준: Aug 28, 2026, 8:00 PM

4.10

+1.99%

애프터마켓: 7:57 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-2.90% (1D)

데이터 없음

매수호가	2.96
시가총액	405.42M
매출 (ttm)	n/a
순이익 (ttm)	-28.03M
	0.35
	-0.43
	n/a
	-2.39
P/B (ttm)	-1.92
P/S (ttm)	n/a
실적 발표일	n/a

매도호가	4.07
거래량	271,101
평균 거래량 (20일)	640,366
시가	4.14
전일 종가	4.14
일중 범위	3.95 - 4.20
52주 범위	2.03 - 7.13
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

GALT 소개

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 4, 2002

직원 수 9

상장 거래소 NasdaqCM

티커 GALT

웹사이트 https://galectintherapeutics.com

전체 기업 정보

재무 실적

2025년 Galectin Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -30.84M로, -34.46% 감소했습니다.

재무제표

어닝 서프라이즈

Galectin Therapeutics가 Aug 14, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.14 예상치 하회 -0.05, 및 -16.67% 전년 대비 감소.

뉴스

2개월 전 · Zacks

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.

2개월 전 · Stocktwits

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

Galectin plans to submit the final trial protocol to the FDA in the third quarter of 2026.

4개월 전 · Zacks

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5개월 전 · MarketBeat

Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps

Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (M...

7개월 전 · Simply Wall St.

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders

Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are...

2 페이지 중 1

Galectin Therapeutics Inc... (GALT)